Paramount Sees Potential Strategic, Commercial Opportunities With Middle East Investors

Paramount Skydance secured roughly $24.0B of the $45.72B equity funding for its proposed $110B enterprise-value acquisition of Warner Bros. Discovery, with $10B from Saudi Arabia, and the transaction also has $54B of debt commitments from Bank of America, Citi and Apollo. The Ellison guarantee requires covering any partner shortfalls, PSKY will issue free warrants to Class B holders (increasing authorized Class B shares from 5.5B to 7B) allowing purchases at a floor of $12 and ceiling of $16.02, and syndicated shares to Middle East investors will be non-voting, replacing a previously planned $16.02 rights offering.

Analysis

The structure (large non-voting stakes + a tradable warrant dividend) shifts the investor base from retail/activist-driven governance toward strategically-aligned, low-voting capital — that will depress free float liquidity and concentrate control, raising future takeover premium thresholds while mechanically amplifying implied volatility in the publicly traded tranche. Because the market will treat the warrants as concentrated long-dated call optionality distributed to a broad holder base, expect elevated retail/relative-value demand into the listing window, compressing implied yields on the equity but also creating a volatile multi-legged re-pricing event around listing and any syndication mark deadlines.

Strategically, sovereign partners create optional pathways for content monetization and regional distribution deals that could lift long-term revenue per title for the combined studio, but those commercial benefits are back-end and lumpy — they require regulatory patience and active deal-making over 12–36 months. The Ellison backstop centralizes ultimate funding tail risk into one high-net-worth sponsor, increasing correlation between the merged entity and his other holdings; that concentration creates a governance-risk beta that will show up in ORCL/large-cap tech sentiment under stress.

Short-term catalysts: warrant listing details, syndication performance updates, and any regulatory/foreign-investment reviews — these can move prices violently in days to weeks. The larger binary is transaction consummation versus delay/renegotiation over months; if the market is pricing certainty, a single sovereign withdrawal or regulatory hold could reset valuations by multiples, so position sizing and event hedges are paramount.

Key Decisions for Investors

• Buy PSKY common and hedge with put protection (3–6 month puts) ahead of the warrant listing window — asymmetric payoff if the deal proceeds and warrants rerate, while puts cap downside if syndication/regulatory issues surface. Position size: 2–4% portfolio; target reward 20–40% vs capped downside to put strike.
• Prepare to buy PSKY warrants on first day of Nasdaq trading (9–12 month horizon) as a leveraged directional play; focus on low-IV entry and liquidity. Risk: total premium loss if deal collapses; reward: 3x+ on exercised/revalued optionality if commercial tie-ups materialize.
• Long NDAQ (calls, 6–12 months) to capture elevated listing and trading volumes from the warrant issuance and any secondary activity; modest position to play fees/flow. Risk: muted if broader market falls; reward: outsized relative performance vs cash equities during elevated ADTV periods.
• Protect the campaign with WBD downside (out-of-the-money puts, 6–9 months) as a pair hedge against deal failure — this is a low-cost tail hedge that pays if the merger unravels and both names reprice. Position size: <1% portfolio; risk limited to option premium, reward scales if transaction derails.